title: Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer.
abstract: Anti-M is usually a naturally occurring cold-reactive immunoglobulin M (IgM) antibody, often with an immunoglobulin G (IgG) component, and is seldom implicated in delayed haemolytic transfusion reactions (DHTR). However, cases have been reported. In the majority, a DHTR is not suspected until further blood is requested and a new antibody is detected on pretransfusion testing. We describe the case of a young man receiving therapy with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) for metastatic renal cell cancer who developed a clinically suspected DHTR that was confirmed serologically to be caused by anti-M, reactive at 37 degrees C. We discuss the possible role of his biochemotherapy in the development of the DHTR.
authors.affiliation: Departments of Haematology and Medicine, Royal Marsden Hospital NHS Trust, London, UK.
authors.forename: N
authors.initials: N
authors.lastname: Parry-Jones
authors.forename: M E
authors.initials: ME
authors.lastname: Gore
authors.forename: J
authors.initials: J
authors.lastname: Taylor
authors.forename: J G
authors.initials: JG
authors.lastname: Treleaven
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D001803:Blood Transfusion; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D006461:Hemolysis / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology*; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D009362:Neoplasm Metastasis; D065227:Transfusion Reaction
chemical_list: D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D016898:Interferon-alpha; D007376:Interleukin-2